Abstract: Provided and described herein are methods and compositions for decreasing blood glucose, reducing an increase in blood glucose, and/or lowering the glycemic index of a foodstuff.

Abstract: This application provides methods and compositions related to constructing nucleic acid hydrogels (e.g., RNA hydrogels) having repetitive monomer units, each monomer unit includes one or more G-quadruplex sequences. These G-quadruplex sequences cross-link the nucleic acid concatemer such that it self-assembles into a hydrogel under appropriate conditions. In some embodiments, each monomeric unit of the nucleic acid concatemer comprises a coding sequence for polypeptide of interest; and the nucleic acid hydrogel formed by the nucleic acid concatemer can be used for expressing the polypeptide in high quantities. In some embodiments, at least two RNA concatemers comprising G-quadruplex sequences are produced, one further comprising a spacer and the other further comprising a sequence encoding a polypeptide of interest. These two RNA concatemers are combined and self assembled to form a single, wideband RNA hydrogel.

Abstract: Provided are a novel polypeptide, a fusion polypeptide comprising the polypeptide, and a use thereof as an antibiotic. More specifically, provided are a novel polypeptide derived from a bacteriophage, a novel fusion polypeptide comprising cecropin A, and an antibiotic against Gram-negative bacteria comprising the polypeptide and/or the fusion polypeptide.

Abstract: Provided are MTSP-1 polypeptides modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to inhibit its activity and thereby inhibit complement activation. The modified MTSP-1 polypeptides that inhibit complement activation can be used for treatment of diseases and conditions in which complement activation plays a role. Such diseases and conditions include inflammatory diseases and diseases with an inflammatory component. Exemplary of these disorders are ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, ophthalmic disorders, such as diabetic retinopathies and macular degeneration, including age-related macular degeneration (AMD), and transplanted organ rejection, such as renal delayed graft function (DGF).

Abstract: The disclosure provides methods and compositions for treating blood diseases/disorders, such as sickle cell disease, hemochromatosis, hemophilia, and beta-thalassemia. For example the disclosure provides therapeutic guide RNAs that target the promotor of HBG1/2 to generate point mutations that increase expression of fetal hemoglobin. As another example, the disclosure provides therapeutic guide RNAs that target mutations in HBB, Factor VIII, and HFE to treat sickle cell disease, beta-thalassemia, hemophilia and hemochromatosis. The disclosure also provides fusion proteins comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA. In some embodiments, the fusion proteins are in complex with nucleic acids, such as guide RNAs (gRNAs), which target the fusion proteins to a DNA sequence (e.g., an HBG1 or HBG2 protmoter sequence, or an HFE, GBB, or F8 gene sequence).

Abstract: Disclosed is a method for extracting high-purity polydeoxyribonucleotide (PDRN) from salmon testes, including 1) separating semen and immature testicular regions from the testes of a salmonid fish, 2) gently grinding the immature testicular regions, followed by dilution with an artificial seminal plasma, 3) treating the dilution with a predetermined concentration of human chorionic gonadotropin (hCG) to induce artificial sexual maturation of the testicular cells to sperm, 4) centrifuging the testicular dilution after the passage of a predetermined time from the hCG treatment and collecting potentially motile sperm, and 5) extracting PDRN from the collected sperm. The method enables the production of raw materials for PDRN with a 100- to 200-fold higher purity from 20 mL (a maximum of 50 mL) of sperm (semen) collected at one time from a salmonid fish. In addition, the method enables the extraction of PDNR in high yield in a cost-effective and economically viable manner.

Abstract: The present invention relates to the field of biotechnologies and in particular to the use of a nucleotide sequence having transcription promoter activity in prokaryotic and eukaryotic cell systems.

Abstract: Disclosed herein are means for the detection and characterization of neurotoxins such as botulinum neurotoxin (BoNT) or tetanus neurotoxin. The present disclosure provides methods for determining potency and activity of neurotoxins in vitro and in vivo. Also disclosed are polypeptides comprising N- and C-terminal fragments of a reporter protein that are split by a linker comprising a neurotoxin cleavage site. Cleavage of the linker by a neurotoxin decreases reporter protein activity, thereby indicating activity of the neurotoxin. Compositions and kits comprising the disclosed polypeptides, nucleic acids comprising nucleotide sequences encoding such polypeptides, and cells expressing such polypeptides are also disclosed.

Abstract: Provided herein are engineered variants of archaeal polymerases that exhibit exonuclease-minus activity, enhanced thermostability, enhanced incorporation of 3? modified nucleotides, improved uracil-tolerance and/or reduce sequence-specific errors in polymerase-catalyzed nucleotide binding and extension reactions relative to wild type polymerase enzymes. Also provided are uses of the engineered polymerases for forming complexed polymerases and forming binding complexes, and uses for conducting nucleic acid sequencing reactions.

Abstract: Provided herein are modified cleavases for removing amino acids from peptides, polypeptides, and proteins. Also provided are methods of using the modified cleavases for treating polypeptides, and kits comprising the modified cleavase. In some embodiments, the methods and the kits also include other components for macromolecule sequencing and/or analysis.

Abstract: Hydroxycarboxylic acids may be biosynthesized from a carbonaceous feedstock and then isolated through forming and subsequently hydrolyzing an intermediate sophorolipid. After biosynthesizing a hydroxycarboxylic acid in a cell culture medium or otherwise providing a hydroxycarboxylic acid in a first aqueous medium, the hydroxycarboxylic acid and glucose may be converted into at least one sophorolipid by a suitable microorganism or an enzyme cocktail. The at least one sophorolipid may be then be separated from the cell culture medium or first aqueous medium and then hydrolyzed in a second aqueous medium to form the hydroxycarboxylic acid and glucose as free components separate from the cell culture medium or first aqueous medium. The hydroxycarboxylic acid is present as a phase separate from the second aqueous medium and the glucose remains in the second aqueous medium.

Abstract: The present disclosure is generally related to novel promoter sequences and methods thereof for enhanced protein production in Bacillus sp. (host) cells. As set forth herein, the novel promoter sequences of the disclosure, when operably linked to a gene or open reading frame encoding a protein of interest, are particularly well suited for use in large scale production of industrially relevant proteins.

Abstract: The technology relates in part to biological methods for producing terpenes and to engineered cells and microorganisms capable of such production.

Abstract: The present disclosure provides compositions and methods for sensing a target substance of interest in the environment and inducing gene expression in response thereto, useful for detection of biological and chemical agents and environmental pollutants.

Abstract: Provided are compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.

Abstract: Provided herein, in some aspects, are polypeptide monomers comprising an angiotensin-converting enzyme 2 (ACE2) ectodomain and an oligomerization domain. Also provided herein are oligomeric complexes comprising ACE2 monomers. Methods of using such to monomers and oligomeric complexes for the diagnosis, prevention, and treatment of viral infections such as the coronavirus are also provided.

Abstract: Provided are a genome editing system CRISPR-C2c1 for site-specific modification of target sequences in a cell genome and the use thereof, wherein the system comprises a C2c1 protein or variants thereof and a guide RNA. Also provided are a method for site-specific modification of target sequences in a cell genome using the genome editing system CRISPR-C2c1, and a pharmaceutical composition comprising the genome editing system CRISPR-C2c1.

Abstract: Disclosed is a product and process, wherein one adds a N-terminal Histamine-Maltose Binding Protein (“MBP”) tag to endonucleases, including restriction endonucleases like Hind III, and binds the tagged fusion protein to a solid support, preferably beads, once the enzyme has digested oligonucleotides in solution, in order to arrest further digestion. Preferred beads for binding the tagged enzyme are magnetic beads, which can easily be removed from solution by binding to a support and then removing it, or can be accumulated by magnetic attraction in a particular region. More preferred are magnetic beads bound to iminodiacetic acid or nitrilotriacetic acid.

Abstract: The present invention relates to an enzyme-catalyzed process for producing UDP-N-acetyl-?-D-glucosamine (UDP-GlcNAc) from low-cost substrates uridine monophosphate and N-acetyl-D glucosamine in a single reaction mixture with immobilized or preferably co-immobilized enzymes. Uridine may be used as starting material instead of uridine monophosphate as well. Further, the process may be adapted to produce GlcNAcylated molecules and biomolecules including saccharides, particularly human milk oligosaccharides (HMO), proteins, peptides, glycoproteins, particularly antibodies, or glycopeptides, and bioconjugates, particularly carbohydrate conjugate vaccines and antibody-drug conjugates.

Abstract: The present invention provides engineered glycosyltransferase (GT) enzymes, polypeptides having GT activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention provides engineered sucrose synthase (SuS) enzymes, polypeptides having SuS activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention also provides compositions comprising the GT enzymes and methods of using the engineered GT enzymes to make products with ?-glucose linkages. The present invention further provides compositions and methods for the production of rebaudiosides (e.g., rebaudioside M, rebaudioside A, rebaudioside I, and rebaudioside D). The present invention also provides compositions comprising the SuS enzymes and methods of using them. Methods for producing GT and SuS enzymes are also provided.